PepGen Business Summary

PepGen Inc. (PEPG) is a clinical-stage biotechnology company that operates primarily through the development of its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. As of early 2026, the company does not generate commercial revenue from product sales, instead sustaining operations through equity financing, strategic collaborations, and potential future milestone-based licensing fees. Its business is segmented by therapeutic focus into two primary clinical programs: PGN-EDO51, targeting Duchenne Muscular Dystrophy (DMD) patients amenable to exon 51-skipping, and PGN-EDODM1, a lead candidate for Myotonic Dystrophy Type 1 (DM1). PepGen competes directly with other oligonucleotide-focused firms such as Avidity Biosciences, Dyne Therapeutics, and Sarepta Therapeutics. Within this landscape, PepGen distinguishes itself by utilizing specialized cell-penetrating peptides designed to achieve superior tissue penetration and nuclear delivery compared to traditional conjugate technologies. The company is led by President and CEO James McArthur, Ph.D., a veteran entrepreneur who co-founded five biotechnology companies, including Imara and Cydan. The executive team was significantly bolstered in 2025 and early 2026 with the appointments of Kasra Kasraian, Ph.D., as Chief Technology Officer—who previously led technical operations at bluebird bio—and Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Other key leaders include Chief Medical Officer Michelle Mellion, M.D., and CFO Noel Donnelly. PepGen is backed by a high-profile roster of institutional investors, including RA Capital Management, which holds a significant stake, alongside Viking Global Investors and Oxford Science Enterprises. The Board of Directors features seasoned industry figures who provide strategic oversight as the company advances its FREEDOM2 clinical trials toward anticipated 2026 data readouts.